Navigation Links
Caliper Life Sciences Introduces Drug Combination Services to Identify Synergistic Response of Compounds
Date:12/3/2007

- Screening Determines Efficacy and Safety of Combination Drug Therapies -

HOPKINTON, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today launched drug combination services through Caliper Discovery Alliances & Services (CDAS). These new services will help researchers determine the efficacy of combination drug therapies and identify potentially harmful combinations before therapies enter clinical trials. Studies, performed in Caliper's anti-cancer cell proliferation panel, cellular cytokine/chemokine release assays or using in vivo efficacy models, will help identify synergistic responses of drug combinations and eliminate antagonistic mixtures of drugs.

Drug combination studies are increasingly valuable to pre-clinical pharmaceutical research. The simultaneous use of a variety of drugs is common today for the treatment of bacterial infections, HIV, hypertension and cancer. Drug combination testing is subsequently a growing trend in many areas including oncology. If a combination is synergistic, lower doses can be used to achieve the same or better efficacy, which can lead to lower toxicity and safer patient care.

"Drug combination studies using cancer cell lines create a relationship between in vitro screening and profiling, and in vivo animal models. This connection is critical as researchers strive to understand how drug combinations may react in humans," said Kevin Hrusovsky, President and CEO, Caliper Life Sciences. "The exact same cell lines used in the in vitro drug combination testing can be used to create in vivo tumor models to further assess efficacy using the IVIS imaging platform."

The CDAS drug combination studies combine the liquid-handling, automation and imaging elements of Caliper's business. Drug combination studies can show whether chemical entities improve the efficacy of existing standard care treatments, providing a possible catalyst to FDA approval and market adoption. Testing combinations in vitro and in vivo also ensures that new clinical compounds will not decrease the effectiveness of standard therapy, thereby avoiding potentially harmful consequences for human study subjects. Drug combination studies also allow clinicians to better optimize the doses used in clinical trials as well.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of leading-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
10. Alfacell Corporation to Present at UBS Global Life Sciences Conference
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/5/2017)... MINNEAPOLIS , July 5, 2017 Pace Analytical, a company of ... announcing today that they have acquired ESC Lab Sciences, further solidifying their position ... the United States . ... Steve Vanderboom- President and CEO of Pace Analytical ... of ESC Lab Sciences out of Mt Juliet, TN , ...
(Date:7/1/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today ... be broadcast live over the Internet on Thursday, July 27, ... the quarterly results will be made available at 7:30 a.m. ... The live audio webcast can be accessed via Zimmer Biomet,s ... archived for replay following the conference call. ...
(Date:6/30/2017)... Medical (AVACEN) announced the publication of new research in the peer-reviewed ... AVACEN Treatment Method to significantly reduce the widespread pain ... ... ... 200 to 400 million people worldwide according to The National Fibromyalgia ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has ... contents of its ginger ale for allegedly containing no ginger. Dr. Pepper produces the ... Group, Inc., plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... 21, 2017 , ... West Dermatology is pleased to announce the newest addition ... 2017, Ms. Vu will join West Dermatology’s large network of medical and cosmetic dermatology ... cancer , and more. She graduated from the University of Florida College of Medicine ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... why concussion rates are on the rise, say researchers presenting their work at ... Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change in ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... bone marrow cancer that progresses rapidly without treatment. Newly diagnosed patients face intense ... chance of reoccurrence and relapse. With such a challenging diagnosis that requires ...
Breaking Medicine News(10 mins):